ALK Abello delivers 18% organic revenue growth

14 November 2024

Danish allergy immunotherapy specialist ALK Abello (ALKB: DC) today posted financial results for the third quarter of 2024, which pleased investors. The company’s shares were up 5.6% at 168.60 kroner in early trading.

Total revenue increased by 18% in local currencies to 1,313 million kroner ($190 million) on broad-based growth.

Earnings before interest and taxes (EBIT) more than doubled to 306 million kroner, with an EBIT margin of 23% (13%). Progress was driven by sales growth, gross margin improvements, and cost optimizations. EBIT included one-off costs of 11 million related to previously announced optimization initiatives.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK